This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Prospective Observational Registry of Peripheral Use of AngioJet Rheolytic Thrombectomy With Mid-Length Catheters

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boston Scientific Corporation
ClinicalTrials.gov Identifier:
NCT00778336
First received: October 22, 2008
Last updated: October 8, 2014
Last verified: October 2014
Results First Received: February 22, 2011  
Study Type: Observational
Study Design: Observational Model: Case-Only;   Time Perspective: Prospective
Conditions: Peripheral Vascular Diseases
Thrombosis
Venous Thrombosis

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients presenting at a participating site who were clinically indicated for a peripheral interventional(venous or arterial) procedure with the mid-length (90cm or 120cm catheters) catheter were offered the opportunity to participate. Patients were recruited from January 2007 thru December 2009.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Limb Ischemia Patients with limb ischemia treated with a midlength AngioJet catheter.
Deep Vein Thrombosis Patients with deep vein thrombosis treated with a midlength AngioJet catheter.
Hemodialysis Access Patients with thrombosed hemodialysis access treated with a midlength AngioJet catheter.
Other Thrombotic Conditions Patients with a thrombotic Condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access treated with a midlength AngioJet catheter.

Participant Flow for 2 periods

Period 1:   Index Procedure-Discharge
    Limb Ischemia   Deep Vein Thrombosis   Hemodialysis Access   Other Thrombotic Conditions
STARTED   198   170   72   12 
COMPLETED   192   167   70   12 
NOT COMPLETED   6   3   2   0 
Death                6                3                2                0 

Period 2:   3 Month Follow Up
    Limb Ischemia   Deep Vein Thrombosis   Hemodialysis Access   Other Thrombotic Conditions
STARTED   192   167   70   12 
COMPLETED   169   144   65   12 
NOT COMPLETED   23   23   5   0 
Lost to Follow-up                15                20                3                0 
Death                8                3                2                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Limb Ischemia Patients with limb ischemia treated with a midlength AngioJet catheter.
Deep Vein Thrombosis Patients with deep vein thrombosis treated with a midlength AngioJet catheter.
Hemodialysis Access Patients with thrombosed hemodialysis access treated with a midlength AngioJet catheter.
Other Thrombotic Conditions Patients with a thrombotic Condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access treated with a midlength AngioJet catheter.
Total Total of all reporting groups

Baseline Measures
   Limb Ischemia   Deep Vein Thrombosis   Hemodialysis Access   Other Thrombotic Conditions   Total 
Overall Participants Analyzed 
[Units: Participants]
 198   170   72   12   452 
Age 
[Units: Years]
Mean (Standard Deviation)
 67  (14)   52  (17)   63  (13)   63  (18)   61  (16) 
Gender 
[Units: Participants]
         
Female   88   64   34   6   192 
Male   110   106   38   6   260 
Region of Enrollment 
[Units: Participants]
         
United States   198   170   72   12   452 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Baseline to Final Angiographic Results   [ Time Frame: Index Procedure ( pre-endovascular treatment and post-endovascular treatment) ]

2.  Secondary:   Rethrombosis   [ Time Frame: 3 Month Follow Up ]

3.  Secondary:   Description of Treatments by Thrombotic Condition   [ Time Frame: Index Procedure ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Non randomized observational registry


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: DeeAnn Tinjum
Organization: Boston Scientific Corporation
phone: 763-450-8707
e-mail: deeann.tinjum@bsci.com



Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT00778336     History of Changes
Other Study ID Numbers: PEARL
Study First Received: October 22, 2008
Results First Received: February 22, 2011
Last Updated: October 8, 2014